BioAffinity Announces 1-for-15 Reverse Split to Regain Nasdaq Compliance
BIAF sits 20% above its 52-week low of $0.325.
Summary
BioAffinity Technologies will execute a 1-for-15 reverse stock split effective at the open on August 24, 2026. The move is a direct response to the Nasdaq delisting notice received July 31 for failing the $1 minimum bid price rule. With the stock at $0.3899, the split would mechanically lift the price to about $5.85, well above the threshold. The company has been burning cash and recently raised $4.0 million in a private placement, but the going concern warning from the Q2 10-Q remains unresolved. The split does not change market cap or fundamentals, but it removes the immediate delisting overhang and may improve institutional eligibility. Traders should note the split-adjusted share count will reduce liquidity and could increase volatility.
Updates
· SEC 8-K — The reverse split becomes effective at 4:01 p.m. ET on August 21, 2026, with trading on a split-adjusted basis starting August 24. The new CUSIP is 09076W406, and post-split shares outstanding will be approximately 592,373.
At the time of this announcement, BIAF was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.33 to $13.50. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.